SCHEMBL2867868

SCHEMBL2867868

CC1(C)OC(=O)N2CCN(C(=O)Oc3ccccc3)CC21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.47
NPSR1 Q6W5P4 2/20 0.44
KMT2A Q03164 5/20 0.43
MGLL Q99685 1/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 1/20 0.41
ADRB2 P07550 1/20 0.41
APLNR P35414 1/20 0.41
GLP1R P43220 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
GPR119 Q8TDV5 1/20 0.41
CYP3A4 P08684 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TSHR P16473 3/20 0.41
MEN1 O00255 3/20 0.41
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 1/20 0.41
ALOX15 P16050 1/20 0.41
CASP3 P42574 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2860641 0.85 NPSR1 (0.62) GAANPSR1KMT2AMGLLNPC1
SCHEMBL2869078 0.84 GAA (0.45) GAANPSR1KMT2AMGLLNPC1
SCHEMBL2861580 0.83 SMN1; SMN2 (0.50) NPSR1KMT2ANPC1RAB9AADRB2
SCHEMBL2865426 0.82 NPSR1 (0.48) GAANPSR1KMT2AMGLLNPC1
SCHEMBL2856550 0.81 GAA (0.43) GAANPSR1KMT2AMGLLNPC1
SCHEMBL2867201 0.80 NPSR1 (0.62) GAANPSR1KMT2AMGLLNPC1
SCHEMBL2864501 0.80 NPSR1 (0.57) GAANPSR1KMT2ANPC1RAB9A
SCHEMBL2861967 0.78 NPSR1 (0.54) GAANPSR1KMT2ANPC1RAB9A
SCHEMBL2870819 0.78 NPSR1 (0.57) GAANPSR1KMT2ANPC1RAB9A
SCHEMBL2867955 0.78 NPSR1 (0.65) GAANPSR1KMT2ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 GAA 4495/4885NPSR1 211/4885KMT2A 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.